No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study - Archive ouverte HAL Access content directly
Journal Articles International Journal of Infectious Diseases Year : 2021

No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study

(1, 2) , (3) , (1, 3) , (3) , (3) , (3) , (3) , (3) , (3) , (3) , (3) , (3) , (3) , (3) , (3) , (4, 5) , (1, 3)
1
2
3
4
5

Abstract

Background: Ceftriaxone and cefotaxime share a similar antibacterial spectrum and similar indications but have different pharmacokinetic characteristics. Ceftriaxone is administered once daily and 40% of its clearance is by biliary elimination, whereas cefotaxime requires three administrations per day and shows less than 10% biliary elimination. The high biliary elimination of ceftriaxone suggests a greater impact of this antibiotic on the gut microbiota than cefotaxime. The objective of this study was to compare the impact of ceftriaxone and cefotaxime on the gut microbiota. Methods: A prospective clinical trial was performed that included 55 patients treated with intravenous ceftriaxone (1 g/24 h) or cefotaxime (1 g/8 h) for at least 3 days. Three fresh stool samples were collected from each patient (days 0, 3, and 7 or at the end of intravenous treatment) to assess the emergence of third-generation cephalosporin (3GC)-resistant Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, Pseudomonas aeruginosa, toxigenic Clostridioides difficile, and vancomycin-resistant enterococci. Results: The emergence of 3GC-resistant gram-negative enteric bacilli (Enterobacteriaceae) (5.9% vs 4.7%, p > 0.99), Enterococcus spp, and non-commensal microorganisms did not differ significantly between the groups. Both antibiotics reduced the counts of total gram-negative enteric bacilli and decreased the cultivable diversity of the microbiota, but the differences between the groups were not significant. Conclusion: No significant difference was observed between ceftriaxone and cefotaxime in terms of the emergence of resistance.
Fichier principal
Vignette du fichier
2021_Pilmis_International Journal of Infectious Diseases.pdf (754.12 Ko) Télécharger le fichier
Origin : Publisher files allowed on an open archive
Licence : CC BY NC ND - Attribution - NonCommercial - NoDerivatives

Dates and versions

hal-03820764 , version 1 (19-10-2022)

Licence

Attribution - NonCommercial - NoDerivatives - CC BY 4.0

Identifiers

Cite

Benoît Pilmis, Olivier Jiang, Assaf Mizrahi, Jean-Claude Nguyen Van, Julie Lourtet-Hascoët, et al.. No significant difference between ceftriaxone and cefotaxime in the emergence of antibiotic resistance in the gut microbiota of hospitalized patients: A pilot study. International Journal of Infectious Diseases, 2021, 104, pp.1-7. ⟨10.1016/j.ijid.2021.01.025⟩. ⟨hal-03820764⟩
0 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More